

**INVESTOR CONTACT:** 

Mark Kimbrough 615-344-2688

FOR IMMEDIATE RELEASE MEDIA CONTACT:

Harlow Sumerford 615-344-1851

#### HCA Healthcare Reports Third Quarter 2021 Results; Revises 2021 Guidance

Nashville, Tenn., October 22, 2021 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended September 30, 2021.

Key third quarter metrics (all percentage changes compare 3Q 2021 to 3Q 2020 unless otherwise noted):

- Revenues totaled \$15.276 billion
- Net income attributable to HCA Healthcare, Inc. totaled \$2.269 billion, or \$7.00 per diluted share
- Adjusted EBITDA totaled \$3.224 billion
- Cash flows from operating activities totaled \$2.277 billion
- Same facility admissions and same facility equivalent admissions increased 6.8 percent and 9.3 percent, respectively

"During the third quarter we experienced the most intense surge yet of the pandemic, and our colleagues and physicians delivered record levels of patient care to meet the demand caused by the Delta variant," said Sam Hazen, Chief Executive Officer of HCA Healthcare. "Once again, the disciplined operating culture and strong execution by our teams were on display. I want to thank them for their tremendous work and dedication to serving others."

Revenues in the third quarter of 2021 increased to \$15.276 billion, compared to \$13.311 billion in the third quarter of 2020. Net income attributable to HCA Healthcare, Inc. totaled \$2.269 billion, or \$7.00 per diluted share, compared to \$668 million, or \$1.95 per diluted share, in the third quarter of 2020. Results for the third quarter of 2021 include gains on sales of facilities of \$1.047 billion, or \$2.43 per diluted share, related to the sale of four hospitals in Georgia and other health care entity investments. Results for the third quarter of 2020 included a reversal of \$822 million, or \$1.72 per diluted share, in government stimulus income recorded in the second quarter of 2020 related to general distribution funds received from the Provider Relief Fund established by the Coronavirus Aid, Relief, and Economic Security ("CARES") Act and \$14 million, or \$0.03 per diluted share, of gains on sales of facilities.

For the third quarter of 2021, Adjusted EBITDA totaled \$3.224 billion, compared to \$2.053 billion in the third quarter of 2020. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

Same facility admissions and equivalent admissions increased 6.8 percent and 9.3 percent, respectively, in the third quarter of 2021, compared to the prior year period. Same facility emergency room visits increased 31.2 percent in the third quarter of 2021, compared to the prior year period. Same facility inpatient surgeries declined 4.9 percent, and same facility outpatient surgeries increased 6.4 percent in the third quarter of 2021, compared to the same period of 2020. Same facility revenue per equivalent admission increased 5.2 percent in the third quarter of 2021, compared to the third quarter of 2020, due to increases in acuity of patients treated and favorable payer mix in the quarter.

Because of the pandemic-related impact on volumes in the third quarter of 2020, the Company believes a comparison of volume statistics to the comparable period in 2019 provides additional context to the improvement in operations during 2021. The following table provides a summary of statistical measures for the third quarter of 2021 compared to the same period in 2019 on a same facility basis.

	Third Quarter		
	2021	<u>2019</u>	% Change
Same Facility:			
Admissions	531,032	517,151	2.7%
Equivalent Admissions	892,665	897,774	-0.6%
Patient Days	2,836,248	2,482,756	14.2%
Equivalent Patient Days	4,767,733	4,310,064	10.6%
Inpatient Surgery Cases	125,533	141,313	-11.2%
Outpatient Surgery Cases	242,450	241,019	0.6%
Emergency Room Visits	2,301,968	2,198,357	4.7%

#### Nine Months Ended September 30, 2021

Revenues for the nine months ended September 30, 2021 totaled \$43.688 billion, compared to \$37.240 billion in the same period of 2020. Net income attributable to HCA Healthcare, Inc. was \$5.142 billion, or \$15.43 per diluted share, compared to \$2.328 billion, or \$6.79 per diluted share, for the first nine months of 2020. Results through September 2021 include gains on sales of facilities of \$1.057 billion, or \$2.39 per diluted share, and losses on retirement of debt of \$12 million, or \$0.03 per diluted share. Results for the nine months ended September 30, 2020 included losses on sales of facilities of \$6 million, or \$0.03 per diluted share, and losses on retirement of debt of \$295 million, or \$0.66 per diluted share.

#### **Balance Sheet and Cash Flows from Operations**

As of September 30, 2021, HCA Healthcare, Inc.'s balance sheet reflected cash and cash equivalents of \$1.027 billion, total debt of \$32.299 billion, and total assets of \$49.562 billion. During the third quarter of 2021, capital expenditures totaled \$889 million, excluding acquisitions. Cash flows provided by operating activities in the third quarter totaled \$2.277 billion, compared to \$2.717 billion in the third quarter of 2020.

During the third quarter of 2021, the Company repurchased 9.605 million shares of its common stock at a cost of \$2.329 billion. The Company had \$2.658 billion remaining under its repurchase authorization as of September 30, 2021. As of September 30, 2021, the Company had \$5.920 billion of availability under its credit facilities.

#### Dividend

HCA today announced that its Board of Directors declared a quarterly cash dividend of \$0.48 per share on the Company's common stock. The dividend will be paid on December 29, 2021 to stockholders of record at the close of business on December 14, 2021.

The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company's financial condition and results of operations and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.

#### 2021 Revised Guidance

The 2021 guidance ranges for the year have been revised from our second quarter release and are as follows:

2021 Guidance Range

Revenues \$58.7 to \$59.3 billion Adjusted EBITDA \$12.50 to \$12.80 billion

EPS (diluted) \$17.20 to \$17.80 per diluted share

Capital Expenditures Approximately \$3.7 billion

The Company's 2021 guidance contains a number of assumptions, including, among others, the Company's current expectations regarding the impact of the COVID-19 pandemic and related government legislation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.

Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.

The Company's guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company's "Forward-Looking Statements."

#### **Earnings Conference Call**

HCA Healthcare will host a conference call for investors at 9:00 a.m. Central Daylight Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed at: <a href="https://investor.hcahealthcare.com/events-and-presentations">https://investor.hcahealthcare.com/events-and-presentations</a>.

#### **About the Company**

As of September 30, 2021, HCA Healthcare operated 183 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.

#### **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company's financial guidance for the year ending December 31, 2021, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan," "initiative" or "continue." These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) developments related to COVID-19, including, without limitation, the length and severity of the pandemic and the spread of virus strains with new epidemiological characteristics; the volume of canceled or rescheduled procedures and the volume of COVID-19 patients cared for across our health systems; measures we are taking to respond to the COVID-19 pandemic; the impact and terms of government and administrative regulation and stimulus (including the Families First Coronavirus Response Act, the CARES Act, the Paycheck Protection Program and Health Care Enhancement Act, the Consolidated Appropriations Act, 2021, the American Rescue Plan Act of 2021 and other enacted and potential future legislation); changes in revenues due to declining patient volumes, changes in payer mix and deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions; supply shortages and disruptions; and the timing, availability and adoption of effective medical treatments and vaccines, (2) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financial perspective, (3) the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "Affordable Care Act"), including the effects of changes or court challenges to the Affordable Care Act or additional changes to its implementation, the possible enactment of additional federal or state health care reforms and possible changes to other federal, state or local laws or regulations affecting the health care industry, including proposals to expand coverage of federally-funded insurance programs as an alternative to private insurance or establish a single-payer system (such reforms often referred to as "Medicare for All"), and also including any such laws or governmental regulations which are adopted in response to the COVID-19 pandemic, (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions, and those required under the Pay-As-You-Go Act of 2010 ("PAYGO Act") as a result of the federal budget deficit impact of the American Rescue Plan Act of 2021, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare

payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (8) the highly competitive nature of the health care business, (9) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (10) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (11) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (12) increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) changes in general economic conditions nationally and regionally in our markets, including economic and business conditions (and the impact thereof on the economy, financial markets and banking industry) resulting from the COVID-19 pandemic, (16) the emergence of and effects related to other pandemics, epidemics and infectious diseases, (17) future divestitures which may result in charges and possible impairments of long-lived assets, (18) changes in business strategy or development plans, (19) delays in receiving payments for services provided, (20) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (21) potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us, (22) the impact of potential cybersecurity incidents or security breaches, (23) our ongoing ability to demonstrate meaningful use of certified electronic health record ("EHR") technology and the impact of interoperability requirements, (24) the impact of natural disasters, such as hurricanes and floods, or similar events beyond our control, (25) changes in the U.S. federal, state, or foreign tax laws including interpretive guidance that may be issued by taxing authorities or other standard setting bodies, and (26) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2020 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management's views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

All references to "Company" and "HCA Healthcare" as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

#### **HCA Healthcare, Inc.**

### **Condensed Consolidated Comprehensive Income Statements**

#### **Third Quarter**

#### (Dollars in millions, except per share amounts)

	2021		2020	
	Amount	Ratio	Amount	Ratio
Revenues	\$15,276	100.0 %	\$13,311	100.0 %
Salaries and benefits	7,094	46.4	6,097	45.8
Supplies	2,463	16.1	2,128	16.0
Other operating expenses	2,530	16.6	2,251	16.9
Government stimulus income reversal	-	-	822	6.2
Equity in earnings of affiliates	(35)	(0.2)	(40)	(0.3)
Depreciation and amortization	716	4.7	694	5.2
Interest expense	398	2.6	385	2.9
Gains on sales of facilities	(1,047)	(6.9)	(14)	(0.1)
	12,119	79.3	12,323	92.6
Income before income taxes	3,157	20.7	988	7.4
Provision for income taxes	685	4.5	209	1.5
Net income	2,472	16.2	779	5.9
Net income attributable to noncontrolling interests	203	1.3	111	0.9
Net income attributable to HCA Healthcare, Inc	\$2,269	14.9	\$668	5.0
Diluted earnings per share	\$7.00		\$1.95	
Shares used in computing diluted earnings per share (millions)	324.029		343.346	
Comprehensive income attributable to HCA Healthcare, Inc	\$2,252		\$715	

#### **HCA Healthcare, Inc.**

# Condensed Consolidated Comprehensive Income Statements For the Nine Months Ended September 30, 2021 and 2020 (Dollars in millions, except per share amounts)

	2021		2020	
	Amount	Ratio	Amount	Ratio
Revenues	\$43,688	100.0 %	\$37,240	100.0 %
Salaries and benefits	19,780	45.3	17,545	47.1
Supplies	7,067	16.2	5,999	16.1
Other operating expenses	7,424	17.0	6,825	18.3
Equity in earnings of affiliates	(78)	(0.2)	(48)	(0.1)
Depreciation and amortization	2,125	4.8	2,059	5.6
Interest expense	1,168	2.7	1,201	3.2
Losses (gains) on sales of facilities	(1,057)	(2.4)	6	-
Losses on retirement of debt	12	-	295	0.8
	36,441	83.4	33,882	91.0
Income before income taxes	7,247	16.6	3,358	9.0
Provision for income taxes	1,531	3.5	665	1.8
Net income	5,716	13.1	2,693	7.2
Net income attributable to noncontrolling interests	574	1.3	365	0.9
Net income attributable to HCA Healthcare, Inc	\$5,142	11.8	\$2,328	6.3
Diluted earnings per share	\$15.43		\$6.79	
Shares used in computing diluted earnings per share (millions)	333.248		343.014	
Comprehensive income attributable to HCA Healthcare, Inc	\$5,152		\$2,273	

### HCA Healthcare, Inc. Condensed Consolidated Balance Sheets (Dollars in millions)

	September 30, 2021	June 30, 2021	December 31, 2020
ASSETS			
Current assets:			
Cash and cash equivalents	\$1,027	\$1,120	\$1,793
Accounts receivable	8,433	7,636	7,051
Inventories	2,019	2,027	2,025
Other	1,769	1,692	1,464
	13,248	12,475	12,333
Property and equipment, at cost	50,695	50,698	49,317
Accumulated depreciation	(27,148)	(27,227)	(26,118)
	23,547	23,471	23,199
Investments of insurance subsidiaries.	418	410	388
Investments in and advances to affiliates	412	382	422
Goodwill and other intangible assets	9,153	8,680	8,578
Right-of-use operating lease assets	2,099	2,118	2,024
Other	685	628	546
	\$49,562	\$48,164	\$47,490
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current liabilities:			
Accounts payable	\$3,759	\$3,531	\$3,535
Accrued salaries	2,134	1,896	1,720
Other accrued expenses	3,481	2,935	3,240
Long-term debt due within one year	250	253	209
	9,624	8,615	8,704
Long-term debt, less debt issuance costs and discounts of \$253, \$255 and \$236	32,049	32,319	30,795
Professional liability risks	1,522	1,585	1,486
Right-of-use operating lease obligations.	1,742	1,767	1,673
Income taxes and other liabilities	2,800	2,088	1,940
Stockholders' equity:			
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.	(695)	(593)	572
Noncontrolling interests.	2,520	2,383	2,320
	1,825	1,790	2,892
	\$49,562	\$48,164	\$47,490

#### HCA Healthcare, Inc.

#### Condensed Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2021 and 2020 (Dollars in millions)

	2021	2020
Cash flows from operating activities:		
Net income	\$5,716	\$2,693
Adjustments to reconcile net income to net cash provided by operating activities:		
Increase (decrease) in cash from operating assets and liabilities:		
Accounts receivable	(1,312)	930
Inventories and other assets	(333)	(36)
Accounts payable and accrued expenses	731	542
Government stimulus refund liability	_	6,123
Depreciation and amortization	2,125	2,059
Income taxes	185	(114)
Losses (gains) on sales of facilities	(1,057)	6
Losses on retirement of debt	12	295
Amortization of debt issuance costs and discounts	21	22
Share-based compensation	341	229
Other	87	66
Ould		
Net cash provided by operating activities	6,516	12,815
Cash flows from investing activities:		
Purchase of property and equipment	(2,385)	(2,087)
Acquisition of hospitals and health care entities	(488)	,
·	` ,	(380)
Sales of hospitals and health care entities	1,980	68
Change in investments	(38)	(40)
Other	2	(44)
Net cash used in investing activities	(929)	(2,483)
Cash flows from financing activities:		
Issuances of long-term debt	4,337	2,700
Net change in revolving credit facilities	500	(2,480)
Repayment of long-term debt	(3,787)	(3,403)
Distributions to noncontrolling interests	(501)	(393)
Payment of debt issuance costs	(38)	(35)
Payment of dividends	(476)	(153)
Repurchase of common stock	(6,143)	(441)
Other	(241)	(156)
Net cash used in financing activities	(6,349)	(4,361)
Effect of exchange rate changes on cash and cash equivalents	(4)	(4)
Change in cash and cash equivalents	(766)	5,967
Cash and cash equivalents at beginning of period	1,793	621
Cash and cash equivalents at end of period	\$1,027	\$6,588
Interest payments	\$1,127 \$1,346	\$1,230 \$779

#### HCA Healthcare, Inc. Operating Statistics

	Third Quarter			For the Nine M onths Ended September 30,	
	 2021	2020	2021	2020	
Operations:					
Number of Hospitals	183	187	183	187	
Number of Freestanding Outpatient Surgery Centers*	123	121	123	121	
Licensed Beds at End of Period	48,950	49,473	48,950	49,473	
Weighted Average Beds in Service	42,088	42,426	42,304	42,304	
Reported:					
Admissions	 536,848	506,756	1,575,269	1,487,992	
% Change	 5.9%		5.9%		
Equivalent Admissions	905,627	835,576	2,654,328	2,447,747	
% Change	 8.4%		8.4%		
Revenue per Equivalent Admission	\$ 16,868	\$ 15,930	\$ 16,459	\$ 15,214	
% Change	 5.9%		8.2%		
Inpatient Revenue per Admission	\$ 18,102	\$ 16,265	\$ 17,115	\$ 15,53	
% Change	 11.3%		10.2%		
Patient Days	 2,865,220	2,593,139	8,166,211	7,476,794	
% Change	 10.5%		9.2%		
Equivalent Patient Days	 4,833,197	4,275,481	13,760,066	12,299,326	
% Change	 13.0%		11.9%		
Inpatient Surgery Cases	 126,436	133,492	390,486	387,228	
% Change	 -5.3%		0.8%		
Outpatient Surgery Cases	 249,192	232,493	742,527	629,723	
% Change	 7.2%		17.9%		
Emergency Room Visits	 2,338,180	1,813,661	6,308,386	5,594,484	
% Change	 28.9%		12.8%		
Outpatient Revenues as a					
Percentage of Patient Revenues	 34.1%	35.5%	36.0%	35.09	
Average Length of Stay (days)	 5.337	5.117	5.184	5.025	
Occupancy (weighted average beds in service)	 74.0%	66.4%	70.7%	64.59	
Same Facility:					
Admissions	 531,032	497,309	1,549,732	1,458,609	
% Change	 6.8%		6.2%		
Equivalent Admissions	 892,665	817,079	2,603,550	2,392,119	
% Change	 9.3%		8.8%		
Revenue per Equivalent Admission	\$ 16,799	\$ 15,962	\$ 16,456	\$ 15,247	
% Change	5.2%		7.9%		
Inpatient Revenue per Admission	\$ 18,055	\$ 16,323	\$ 17,148	\$ 15,610	
% Change	 10.6%		9.9%		
Inpatient Surgery Cases	125,533	131,957	386,190	382,12	
% Change	-4.9%		1.1%		
Outpatient Surgery Cases	 242,450	227,918	724,914	616,082	
% Change	 6.4%		17.7%		
Emergency Room Visits	 2,301,968	1,753,887	6,162,206	5,419,887	
% Change	 31.2%		13.7%		

<sup>\*</sup> Excludes freestanding endoscopy centers (21 centers at both September 30, 2021 and September 30, 2020).

## HCA Healthcare, Inc. Supplemental Non-GAAP Disclosures Operating Results Summary (Dollars in millions, except per share amounts)

	Third Quarter		For the Nine Months Ended September 30,	
	2021	2020	2021	2020
Revenues	\$15,276	\$13,311	\$43,688	\$37,240
Net income attributable to HCA Healthcare, Inc.	\$2,269	\$668	\$5,142	\$2,328
Losses (gains) on sales of facilities (net of tax)	(788)	(10)	(795)	9
Losses on retirement of debt (net of tax)	-	-	9	227
Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales				
of facilities and losses on retirement of debt (a)	1,481	658	4,356	2.564
Depreciation and amortization	716	694	2,125	2.059
Interest expense	398	385	1,168	1,201
Provision for income taxes	426	205	1,272	730
Net income attributable to noncontrolling interests	203	111	574	365
Adjusted EBITDA (a)	\$3,224	\$2,053	\$9,495	\$6,919
Adjusted EBITDA margin (a)	21.1%	15.4%	21.7%	18.6%
Diluted earnings per share:				
Net income attributable to HCA Healthcare, Inc.	\$7.00	\$1.95	\$15.43	\$6.79
Losses (gains) on sales of facilities	(2.43)	(0.03)	(2.39)	0.03
Losses on retirement of debt	-	` -	0.03	0.66
Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales				
of facilities and losses on retirement of debt (a)	\$4.57	\$1.92	\$13.07	\$7.48
Shares used in computing diluted earnings per share (millions)	324.029	343.346	333.248	343.014

<sup>(</sup>a) Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles ("GAAP"). We believe net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

# HCA Healthcare, Inc. Supplemental Non-GAAP Disclosures 2021 Operating Results Forecast (Dollars in millions, except per share amounts)

	For the Year Ending		
	December 31, 2021		
	Low	<u>High</u>	
Revenues	\$58,700	\$59,300	
Net income attributable to HCA Healthcare, Inc. (a)	\$5,650	\$5,830	
Depreciation and amortization	2,840	2,860	
Interest expense	1,560	1,580	
Provision for income taxes	1,700	1,750	
Net income attributable to noncontrolling interests	750	780	
Adjusted EBITDA (a) (b)	\$12,500	\$12,800	
Diluted earnings per share:			
Net income attributable to HCA Healthcare, Inc.	\$17.20	\$17.80	
Shares used in computing diluted earnings per share (millions)	329.000	329.000	

The Company's forecasted guidance range is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry.

Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

<sup>(</sup>a) The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy.

<sup>(</sup>b) Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles ("GAAP"). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams.